Monopar Therapeutics (NASDAQ:MNPR) Shares Up 3.1% – Time to Buy?

Monopar Therapeutics Inc. (NASDAQ:MNPR)’s stock price shot up 3.1% during mid-day trading on Wednesday. The stock traded as high as $82.32 and last traded at $82.04. 20,994 shares traded hands during mid-day trading, a decline of 90% from the average session volume of 210,178 shares. The stock had previously closed at $79.57.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on MNPR shares. HC Wainwright upped their price target on Monopar Therapeutics from $105.00 to $125.00 and gave the stock a “buy” rating in a research note on Wednesday, July 22nd. Barclays reaffirmed an “overweight” rating and issued a $145.00 target price (up from $128.00) on shares of Monopar Therapeutics in a research report on Friday, September 11th. Zacks Research lowered shares of Monopar Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, August 13th. Cantor Fitzgerald cut shares of Monopar Therapeutics from an “overweight” rating to a “neutral” rating and lifted their price target for the company from $109.00 to $119.00 in a research report on Thursday, August 13th. Finally, Morgan Stanley reissued an “overweight” rating and set a $130.00 price objective on shares of Monopar Therapeutics in a research note on Monday, August 17th. Two investment analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $122.00.

Monopar Therapeutics Stock Up 0.2%

The company has a market cap of $563.67 million, a P/E ratio of -38.70 and a beta of 1.50. The company has a fifty day moving average of $104.93 and a 200 day moving average of $83.54.

Monopar Therapeutics (NASDAQ:MNPR) last announced its earnings results on Wednesday, August 12th. The company reported ($0.62) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.64) by $0.02. As a group, research analysts forecast that Monopar Therapeutics Inc. will post -2.98 EPS for the current year.

Insider Buying and Selling at Monopar Therapeutics

In other Monopar Therapeutics news, Director Kim R. Tsuchimoto sold 4,090 shares of the business’s stock in a transaction dated Wednesday, August 26th. The stock was sold at an average price of $111.39, for a total transaction of $455,585.10. Following the completion of the sale, the director owned 7,396 shares of the company’s stock, valued at approximately $823,840.44. The trade was a 35.61% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Raymond Anderson sold 3,142 shares of the stock in a transaction that occurred on Tuesday, August 25th. The stock was sold at an average price of $111.77, for a total transaction of $351,181.34. Following the completion of the sale, the director directly owned 23,751 shares of the company’s stock, valued at $2,654,649.27. This represents a 11.68% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 44,688 shares of company stock worth $4,023,094. 9.70% of the stock is owned by insiders.

Institutional Investors Weigh In On Monopar Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the stock. Caitong International Asset Management Co. Ltd bought a new position in shares of Monopar Therapeutics during the fourth quarter worth $86,000. Your Advocates Ltd. LLP purchased a new position in shares of Monopar Therapeutics during the first quarter valued at about $183,000. The Manufacturers Life Insurance Company bought a new stake in shares of Monopar Therapeutics in the first quarter worth about $250,000. Sei Investments Co. grew its holdings in Monopar Therapeutics by 9.5% during the 1st quarter. Sei Investments Co. now owns 7,582 shares of the company’s stock valued at $415,000 after buying an additional 656 shares in the last quarter. Finally, Virtu Financial LLC bought a new stake in Monopar Therapeutics in the 4th quarter worth approximately $654,000. 1.83% of the stock is owned by hedge funds and other institutional investors.

About Monopar Therapeutics

Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing treatments and diagnostic agents for cancer. The company’s research programs are designed to address serious diseases by using targeted approaches intended to improve the effectiveness and tolerability of oncology therapies.

Monopar’s portfolio has included camsirubicin, a next-generation anthracycline being developed for patients with advanced soft tissue sarcoma. The company has also developed MNPR-101, a therapeutic and imaging platform directed at the urokinase plasminogen activator receptor (uPAR), a protein associated with various aggressive cancers.